William Farrar, MD

The James Cancer Center
William Farrar

Clinical Expertise

  • Surgical Oncology
  • Breast Cancer
  • Parathyroid Cancers
  • Hereditary Breast and Ovarian Cancer Syndrome
Insurance Information



Make an Appointment


I am a surgical oncologist specializing in the treatment of patients with breast cancer.

I’ve held a number of institutional, state and national leadership roles over the course of my career, I currently serve as interim chief executive officer of the James Cancer Hospital and Solove Research Institute. I served as director of surgical oncology at The James for 28 years and also as director of medical affairs for The James for 22 years.

I have served on numerous national committees including, the Training Directions Committee for the Society of Surgical Oncology, the Joint Council for the Approval of Advanced Training in Head and Neck Surgery, and The American College of Surgeons Committee on Cancer.

I am principle investigator PI for the NSABP Clinical Trial Group at The Ohio State University.

I have authored or co-authored of more than 100 clinical studies and reviews published in scientific journals. My clinical research accomplishments have included studies published on such subjects as genetic counseling, sentinel lymph node mapping and biopsy, a procedure to determine if cancer cells have spread from the tumor to lymph nodes in the armpit.

I have earned many national accolades, including the “Best Doctors in America” listing, of which I am a 16-time recipient. I was rated in the top 10 percent of physicians in the nation for patient satisfaction in 2017.

Education and Background


  • University of Virginia Hospitals

    Charottesville, VA


  • Surgical Oncology

    Memorial Sloan-Kettering Cancer Center

    New York, NY

Board Certifications

  • American Board of Surgery

Academic Department

  • Department of Surgery
  • Division of Surgical Oncology

I see patients at

Stefanie Spielman Comprehensive Breast Center

1145 Olentangy River Road, Columbus, Ohio 43212


Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 3/28/2017, Dr. Farrar has reported no financial relationships with medical device, research and/or drug companies.


  • NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

    Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R

    J Natl Compr Canc Netw 15


  • Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.

    Manders JB, Kuerer HM, Smith BD, McCluskey C, Farrar WB, Frazier TG, Li L, Leonard CE, Carter DL, Chawla S, Medeiros LE, Guenther JM, Castellini LE, Buchholz DJ, Mamounas EP, Wapnir IL, Horst KC, Chagpar A, Evans SB, Riker AI, Vali FS, Solin LJ, Jablon L, Recht A, Sharma R, Lu R, Sing AP, Hwang ES, White J, Study investigators and study participants

    Ann Surg Oncol 24


Clinical Trials | Lead

Back to Find a Doctor Search

Make an Appointment


Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator


Please enter a keyword (i.e. Name, Location) or choose a Cancer Type